Discussion about this post

User's avatar
Hedge Fund Guy's avatar

Hi Sean, thanks for the great write up! I saw you mentioned that "VERA [is] a biotech that has a big FDA Decision coming up probably today or tomorrow" and was wondering if — given how binary that outcome is for shareholders — there's been any chatter about the board exploring a sale of the company as a way to de-risk value ahead of (or instead of waiting on) the decision, rather than leaving holders fully exposed to a pass/fail FDA outcome?

No posts

Ready for more?